This Alnylam promotional website is intended for UK Healthcare Professionals Only. Adverse Event Reporting information can be found at the bottom of the page. Prescribing Information links can be found with the content that they relate to.

International Paediatric Transplant Association (IPTA) 2025 Congress, Germany

International Paediatric Transplant Association (IPTA) 2025 Congress, Germany

Primary Hyperoxaluria Type 1 (PH1)

International Paediatric Transplant Association (IPTA) 2025

Congress Details

18-21 September 2025 | Germany

Berlin, Germany

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to lumasiran. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Congress Materials

Kidney-function

Presentation Type

Presentation

Location

Berlin, Germany

Title

Renal Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Long-term Lumasiran Treatment

Access Prescribing Information

American-Society-of-Nephrology-Houston-TX-Mobile

Primary Hyperoxaluria Type 1 (PH1)

American Society of Nephrology (ASN) 2025

6-9 November, 2025 TX

Preparation Date

March 2026

Job Code

MB-UK-00086

European-Society-for-Paediatric-Nephrology,Athens,Greece-Mobile

Primary Hyperoxaluria Type 1 (PH1)

European Society for Paediatric Nephrology (ESPN) 2025

15-18 October, 2025 Greece

Preparation Date

March 2026

Job Code

MB-UK-00085

European Society for Paediatric Urology (ESPU) 2025 Congress, Austria

Primary Hyperoxaluria Type 1 (PH1)

European Society for Paediatric Urology (ESPU) 2025

3-6 September 2025 AUSTRIA

Preparation Date

March 2026

Job Code

MB-UK-00089

European Society for Paediatric Urology (ESPU) 2025 Congress, Austria

Primary Hyperoxaluria Type 1 (PH1)

European Renal Association (ERA) 2025

4-7 June 2025 Austria

Preparation Date

March 2026

Job Code

MB-UK-00091

Primary Hyperoxaluria Type 1 (PH1)

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial

American Journal of Kidney Diseases

Author(s)

Anne-Laure Sellier-Leclerc, Daniella Magen, Hadas Shasha-Lavsky, et al

March 2025

Access Now Lumasiran Prescribing Information

Preparation Date

March 2026

Job Code

MB-UK-00171

International Paediatric Nephrology Association (IPNA) 2025 Congress, South Africa

Primary Hyperoxaluria Type 1 (PH1)

International Pediatric Nephrology Association (IPNA) 2025

19-23 February, 2025 SA

Preparation Date

March 2026

Job Code

MB-UK-00093

Preparation Date

March 2026

Job Code

MB-UK-00088

Login and Sign up

Left Image

RNAiScience is for healthcare professionals. By creating an account, you will have access to:

- All RNAi on-demand educational content
- Personalisation experience with ability to bookmark content for future reference

First Name *

Last Name *

Enter your Institution Email *

Password *

Country *

GMC or GPhC or NMC Number

Select Speciality *

Select Profession *

* Required Fields

By signing up, you agree to our Terms of Service and Privacy Policy.